Objective: To examine different aggrecanase generated fragments in synovial fluid (SF) from patients with acute and chronic knee injuries and from knee healthy subjects. Methods: We prepared SF-D1 samples from acute (n ¼ 35) and chronic (n ¼ 35) knee injury patients and knee healthy subjects (n ¼ 10). Aggrecan fragments were analyzed in the SF-D1 samples by quantitative (G1, ARGS, KEEE and G3 antibodies) and non-quantitative (GRGT and AGEG antibodies) Western blot. Results: ARGS-SELE, ARGS-chondroitin sulfate (CS)1, GRGT-, GLGS-and AGEG-G3 fragments were the main ARGS and G3 fragments in injured and reference samples. In the acute injury samples the concentrations of these fragments were increased compared to the reference, and the level of the ARGS-SELE remained elevated for at least 2 years after the joint injury. Both SF ARGS fragments and aggrecanase generated G3 fragments had high sensitivity and specificity as biomarkers in distinguishing injured from healthy knee joints, although the ARGS fragments had higher area under the receiver operating characteristic curve (AUC) values for injuries (74e86%) than the G3 fragments (AUC values 63e68%). Conclusion: Our results suggest that during the acute phase after knee injury there is an increased aggrecanase activity against both the interglobular domain (IGD) and the CS2 cleavage sites of joint cartilage aggrecan. This increase in SF aggrecanolytic fragments is present for several years after the injury. SF ARGS fragments are better biomarkers than the aggrecanase generated G3-fragments in distinguishing injured from healthy knee joints.
Introduction
Articular cartilage degradation is a hallmark of arthritis and joint injuries, involving an early loss of aggrecan fragments into synovial fluid (SF) 1e3 . Although both matrix metalloproteases (MMPs) and calpains have shown to cleave aggrecan 4 LGQR sites was first shown in bovine explant cultures 7, 8 and later verified in bovine in vitro studies 9, 10 . MMP proteolysis in the IGD at the IPEN 360 Y 361 FFGV site was first shown in pig 11 and human 12 aggrecan, while MMP cleavage in the CS1 region was first shown in bovine aggrecan 13 . Several papers have reported on proteoglycan degradation taking place following knee joint injuries 1e3, 14, 15 , but there are only few papers providing details of the fragments generated during aggrecan turnover 16e18 . Quantitative analysis of aggrecan proteolytic fragments has been conducted by enzyme-linked immunosorbent assay (ELI-SA) 15,19e26 , electrochemiluminescence 27 and by mass spectrometry 28 . Western blot is considered a qualitative method, but is also readily used for quantitative measurements 29e31 . We recently developed a method for quantitative Western blot analysis of aggrecan fragments 18, 32 . In analysis of biological events and in searching for new biomarkers, Western blot has an advantage over conventional screening methods in differentiating fragments of different sizes sharing the same epitope, providing a detailed molecular pattern.
In the process of learning more about cartilage degradation following joint injuries, we here combine a detailed fragment analysis with the advantage of quantitative screening in Western blot to examine aggrecan fragments in SFs from patients with acute and chronic knee joint injuries and from knee healthy subjects. The results provide a detailed mapping and quantitation of aggrecanase generated fragments present in SF after human joint injuries.
Materials and methods

Antibodies and enzymes
Human recombinant ADAMTS-4 (a disintegrin and metalloproteinase with thrombospondin motifs, aggrecanase-1) and aggrecan neo-specific anti-ARGSVILTVK monoclonal antibody (characterized e Supplementary data Fig. S1 ; Refs. 17, 22 ) were kind gifts from M Pratta and Dr. S Kumar (GlaxoSmithKline). Polyclonal aggrecan G1 (#PA1-1747) and G3 (#PA1-1745) domain antibodies (recognizing the sequences: G1, CATEGQVRVNSIYQKVSL; G3, CDGHPMQFENWRPNQPDN) were from Affinity BioReagents (Golden, CO., USA). The specificity of these antibodies was confirmed by Western blot blocking experiments (Supplementary data Fig. S1 ). Aggrecan neo-specific anti-KEEE serum and anti-AGEG serum were kind gifts from Dr. M Lark (Merck) and from M Pratta and Dr. S Kumar (GlaxoSmithKline), respectively. An aggrecan neo-specific anti-GRGT serum was made by Innovagen (Lund, Sweden). Specificity of these antibodies was confirmed by Western blot blocking using immunogen peptides: CEVAPTTFKEEE, AGEGPSGILELC and GRGTI-GISC (Supplementary data Fig. S1 ). All Western blot blocking experiments were done using 10 mM immunogen-peptides incubated with antibody for 30 min at 22 C prior addition to membrane. Peroxidase conjugated secondary antibodies were from Cell Signaling Technology (goat anti-mouse IgG #7076), and from Kirkegaard & Perry Laboratories (KPL) (goat anti-rabbit IgG #074-1516).
Human SF samples
A SF osteoarthritis (OA) epool was made as described 33 . SF was individually collected from 70 patients with knee injuries (35 acute and 35 chronic) and from 10 knee healthy reference (REF) subjects (Table I) . Some of these SF samples have been used in previous biomarkers studies 3 . All procedures were approved by the ethics review committee of the Medical Faculty of Lund University.
Aggrecan SF-D1 isolation from SF
Mini SF-D1 preparations, collecting the lower half of the fractions, were done in the presence of protease inhibitors from 35 acute injury (AI), 35 chronic injury (CI) and 10 REF subjects as described 18 . Sulfated glycosaminoglycan (sGAG; Alcian blue precipitation) and protein (Pierce Micro BCAÔ Assay) analysis of SF and SF-D1 samples were conducted as described 17 . The average sGAG yield in the SF-D1 samples was 77% [standard deviation (SD) ¼ 15, n ¼ 79]. There was no correlation (r S ¼ 0.062, P ¼ 0.59; n ¼ 79) between the sGAG yield (range 45e124%) in SF-D1 and the amount SF sGAG loaded (16e546 mg) on the CsCl gradients, suggesting that the sGAG yields are not a result of differences of sGAG loaded. The SF-D1 samples were deglycosylated by chondroitinase ABC, keratanase and keratanase II and stored in lithium dodecyl sulfate (LDS)esample buffer (Invitrogen) at À20 C
.
Quantification of aggrecan G1, ARGS, KEEE and G3 fragments by Western blot ARGS standard was made as described 18 , by ADAMTS4 digestion of human OA cartilage A1D1 fraction, and the standard was thereafter deglycosylated 17 . The digest was assessed for complete conversion by Western blot using G1, ARGS and TEGE antibodies (data not shown). The human OA cartilage A1D1 fraction, which the ARGS standard was made from, contained no ARGS fragments in vivo 33 and only 39% of full length G1eG3 monomers 32 . Therefore we used an aggrecan molecular weight of 1.5 Â 10 6 g/mol (i.e., for total protein sequence plus sGAG) which corresponds to 0.667 nmol ARGS fragments per mg aggrecan dry weight. A bovine cartilage aggrecan A1D1 fraction, prepared from calf (8e14 months old) metacarpophalangeal joints 17 , was used as G1 and G3 standards. This bovine A1D1 fraction contained 76.3% (mean value; SD ¼ 9%, n ¼ 9 WB experiments) of full length monomers (G1eG3 fragments), and by using full length molecular weight of 2.5 Â 10 6 g/mol (¼0.4 nmol/mg), we assumed that the G1 and G3 standards contained 0.305 nmol (i.e., 0.763 Â 0.4 nmol/mg) G1eG3 fragments per mg aggrecan dry weight. Since no KEEE standards were available, the SF D1 OA pool was used as a control sample for the quantification of KEEE fragments, expressing the data as relative units of the control sample. Subject SF D1 and the OA pool were run on same gels. Due to shortage of subject SF-D1 samples, only one Western blot experiment (with all available D1-samples) was run for detection of KEEE fragments.
Deglycosylated SF D1 samples and standards (i.e., ARGS, G1 and G3 standards; three different concentrations per gel) were denatured as described 17 , and together with Molecular weight markers (10e250 kDa; Precision Plus Protein Standards BIO RAD) separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 3e8% Tris-acetate midi-gels (26-wells, Invitrogen). The proteins were electrophoretically transferred at 40 V for 70 min onto polyvinylidene fluoride (PVDF) membranes (BIO RAD #1620230) using a Criterion Blotter (BIO RAD #170-4070) and cooled 1Â NuPAGE transfer buffer (Invitrogen #NP0006) containing 10% methanol and 0.01% w/v SDS. Immuno-reactions were done as described 17 , using anti-G1 (1.5 mg/ml), anti-ARGS (5.3 mg/ml), anti- 
Statistics
KruskaleWallis one way analysis of variance on ranks was used to avoid mass significance due to multiple group comparisons. If significances were found, then ManneWhitney rank sum tests for analysis of unmatched pairs were run. For correlation analysis, Spearman rank order correlation (r S ) was used. P-values < 0.05 were considered significant. Receiver operating characteristic (ROC) curve analysis was done with Statistical Package for Social Sciences (SPSS) software version 17.0.
Results
Quantitative Western blot screening of ARGS and G3 fragments
The aggrecan fragments detected by Western blot in the subjects' SF-D1 fractions and discussed here are illustrated in Fig. 1 . For each of the ARGS and G3 antibodies each subject's SF-D1 sample, together with standards, were analyzed three times by SDS-PAGE and immuno blotting (i.e., n ¼ 3 different Western blot experiments). For each subject; the mean, median, SD and coefficient of variation (CV) of aggrecan fragment concentrations were calculated. All data were corrected for the sGAG yields in the SF-D1 preparations, assuming that identical types of fragments were present in the recovered vs unrecovered material.
The within-patient CVs (based on the triplicates) for the total ARGS signal varied between the subjects, with an overall average (n ¼ 77 subjects) of 25%. The average CV for ARGS regions A and B was 40% and 29%, respectively (Supplementary data Table SI ). Similar analysis of the G3 aggrecan fragments showed average CVs between 41 and 64% (Supplementary data Table SI ). Due to the high CV values, the median value for each patient was used for the calculation of group medians used in the comparisons between diagnostic groups.
SF aggrecanase generated ARGS fragments are increased following injury
Aggrecan fragments were purified by CsCl density centrifugation from SF of individuals, collecting the D1-fractions from the ARGS-CS1 fragment with a C-terminal previously identified as calpain generated EDLS 1472 (Refs. 18, 32 ). The B-region contained 393 ARGS-CS1 fragments with multiple C-terminals previously estimated as MMP generated GV(G/E)D 952e1409 (Refs. 17, 18 ). In addition, approximately 50% of the injury patients (acute and chronic) and 10% of the knee healthy controls (reference) had an additional 390 kDa ARGS-CS2 fragment (band-a1) with an estimated (using a calculation model) 34 . S2 ). In the AI groups the total ARGS concentration was 33 times (AI, 0e2 weeks) and five times (AI, 2e12 weeks) higher than in the REF group, while in the CI groups (52e104 weeks and >104 weeks) the total ARGS signal did not differ from the reference level [ Fig. 2(a) , Table II ]. In the injury groups, ARGS fragments constituted 5e28% of total aggrecan, and were significantly increased for many years compared to reference levels (Table III) . Both ARGS region-A and -B concentrations were increased in the AI groups (99 times for ARGS region-A in the 0e2 weeks group). While the ARGS region-A level Concentration of aggrecan ARGS-fragments in the study groups. Total ARGS, ARGS region-A (280e310 kDa) and region-B (120e160 kDa) were quantified in SF-D1 samples by Western blot using ADAMTS4 digested human cartilage-A1D1 fraction as ARGS-standards. The boxes define the twenty-fifth and seventy-fifth percentile with a line at the median, error bars define the tenth and ninetieth percentile and circles represent individual outliers. *Indicates significance (P < 0.05) between injury and reference groups. Actual P-values are shown in Table II . Diagnostic groups are as in Table I . was increased up to 2 years after injury, the ARGS region-B concentration had returned to the reference level in the chronic groups [ Fig. 2(b and c) , Table II ]. The ARGS region A/B ratio was higher in both AI and CI groups when compared to the reference [ Fig. 2(d) , Table II ], and the level of the 390 kDa ARGS-CS2 fragment (band-a1) was increased in the CI group compared to the reference (P ¼ 0.007, data not shown). These results confirm previous observations of a marked release of aggrecanase-generated ARGS fragments in the acute phase following injury, and that ARGS fragments represent a large proportion of total aggrecan in these SF samples. Further, although the overall SF ARGS concentration did not significantly differ from reference level 2 years after injury, the differences in ARGS region fragment A and B proportions between injury and control groups suggest a persistent change in aggrecan turnover many years after the joint injury.
G3
SF aggrecanase generated CS2-G3 fragments are increased following injury
The G3 Western blot showed that the SF D1-fractions prepared from the subjects contained G1eG3 monomers (>400 kDa), and aggrecanase generated 214 kDa 1565 GRGT-G3, 171 kDa CS2-G3, 137 kDa 1839 AGEG-G3 and 103 kDa CS2-G3 fragments (Supplementary data Fig. S3 ). The GRGT and AGEG N-terminals of these CS2-G3 fragments were verified by neo-epitope antibodies, while the 103 and 171 kDa CS2-G3 fragments were estimated by calculation 34 as 1939 LGQR-G3 and 1734 GLGS-G3, respectively (Fig. 3) . The SF concentrations of full length G1eG3 monomers did not differ significantly between the injury and reference groups [ Fig. 4(a) , Table IV ]. The LGQR-G3 fragment was only found in some of the injured and none of the uninjured samples, and was therefore not analyzed further (data not shown). On the other hand the GRGT-, GLGS-and AGEG-G3 were the dominant G3 fragments in both injured (mean ¼ 79% of total G3-signal, SD ¼ 21%, n ¼ 68) and reference (mean ¼ 70% of total G3-signal, SD ¼ 26%, n ¼ 9) samples, but the SF concentrations of the aggrecanase generated GRGT-, GLGS-and AGEG-G3 fragments were increased in the AI samples compared to the reference, where the AGEG-G3 fragment increased most (12 times, in the 0e2 weeks AI group) [ Fig. 4(bed) , Table IV] . At 2 years after injury the SF concentrations of these G3-fragments did not differ from the reference levels [ Fig. 4(bed) , Table IV ].
The relative amounts of aggrecanase generated G3 fragments in the SF reference fluids were [GLGS-G3] > [GRGT-G3] > [AGEG-G3], although in the 0e2 weeks AI group the AGEG-G3 was the dominant G3 fragment (Table IV) . The relative proportion of these G3 fragments differed between the AI group (0e12 weeks) and the reference (lower proportions of GRGS-and GLGS-G3 fragments and higher proportion of AGEG-G3), but the proportions were normalized in the CI group (>52 weeks) [ Fig. 4(e) ].
These results suggest that aggrecanase activity against sites in the CS2 region is increased directly after injury, which results in high SF concentrations of GRGT-, GLGS-and AGEG-G3 fragments. Further, the SF concentrations of these G3-fragments are reduced to reference levels at 2 years from injury.
ARGS and G3 fragments as biomarkers for joint injuries
There were no differences in the SF median total ARGS concentration (measure of the aggrecanase cut in the IGD) between men and women comparing all (P ¼ 0.576) or only injured subjects (P ¼ 0.383). Similarly, there were no differences between genders in the SF median GRGT-, GLGS-and AGEG-G3 fragment concentrations (measure of aggrecanase cuts in the CS2 region) of all (P ¼ 0.138, ¼0.155 and ¼0.208 respectively) or only injured subjects (P ¼ 0.102, ¼0.115 and ¼0.150 respectively).
The sensitivity and specificity was high for aggrecanase generated SF ARGS (ARGS region-A, -B and total ARGS) and G3 (GRGT-G3, GLGS-G3 and AGEG-G3) fragments as markers for joint injuries (i.e., AI alone or AI þ CI) ( Table V) . There were no major differences Table III Concentration of sGAG, aggrecan and ARGS fragments in human SF samples. Concentration of total aggrecan (pmol/ml SF) was calculated from the Alcian Blue sGAG concentration (mg GAG/ml SF) assuming that 75% of total aggrecan molecular weight (Mw) comes from GAG and assuming a aggrecan total Mw of 1,500,000 g/mol. Proportion ARGS (%) is the estimated proportion of ARGS fragments out of total amount aggrecan. Concentrations, expressed as median (minemax range) values in diagnostic groups. Median values of sGAG and proportion ARGS were normalized (Norm) against the reference group. P-values, significant analysis (ManneWhitney) of injury vs reference group. Diagnostic groups were according to Fig. 3 . Aggrecanase generated CS2-G3 fragments detected in SF-D1 fractions. Four major aggrecanase generated CS2-G3 fragments were detected in the SF-D1 fractions from the subjects (see Supplementary Fig. S3 ): to identify the N-terminal of these fragments, the SF-D1 OA pool (SF), cartilage A1D1-aggrecan (C) and ADAMTS-4 in vitro digested cartilage A1D1-aggrecan (C1-C3) was separated by SDS-PAGE (3e8%, 15 wells gel), transferred to PVDF-membrane and probed with anti-GRGT (sera, 1:1,000), -AGEG (sera, 1:1,000) and -G3 (2 mg/ml) antibodies as previously 33 . The data confirm the presence of aggrecanase generated GRGT-G3 (214 kDa) and AGEG-G3 (137 kDa) fragments in the SF-D1 samples, and the Mw migration pattern of G3 fragments also suggests the presence of GLGS-G3 (171 kDa) and LGQR-G3 (103 kDa) fragments. 0.5e4 mg sGAG of samples was loaded per lane. C, cartilage A1D1; C1, cartilage A1D1 digested for 15 min with ADAMTS-4; C2, cartilage A1D1 digested for 24 h with ADAMTS-4; C3, cartilage A1D1 digested for 0.5 h with ADAMTS-4. Cartilage A1D1 was prepared from a cartilage OA-pool and the ADAMTS-4 in vitro digest was as previously 17 . D ¼ dimer of the AGEG-G3 fragment. Band marked by þ is considered to be a false-positive immunoband since it could not be blocked by the corresponding immunogen peptide.
between the ARGS markers (ARGS region-A, -B and total ARGS), although all of them had higher area under the ROC curve (AUC) values for AI (94e98%) and for AIs plus CIs (74e86%) compared to corresponding AUC values (AI, 72e83%; AI þ CI, 63e68%) of the G3 fragments (Table V) .
These results suggest that of the high Mw aggrecan fragments found in SF-D1 samples, ARGS fragments are better biomarkers in distinguishing injured from healthy knee joints compared to aggrecanase generated G3 fragments (i.e., GRGT-G3, GLGS-G3 and AGEG-G3), and that gender has no influence in these comparisons.
Differences in the high Mw SF aggrecan fragment pattern between injured and knee healthy subjects visualized by Western blot
The 80 SF-D1 samples were screened for high Mw (i.e., sGAG containing) aggrecan fragments by Western blot with antibodies recognizing G1 and G3 domains, and with antibodies against aggrecanase generated neoepitope ARGS and KEEE.
As shown above the aggrecanase generated ARGS region-A and -B, and band-a1, were all increased compared to the reference following injury [ Fig. 5(a)] . Similarly, the GRGT-G3, GLGS-G3 and a c b d
e Fig. 4 . Concentration of aggrecan G3-fragments in the study groups. G3 fragments were quantified in SF-D1 samples by Western blot using bovine cartilage-A1D1 fraction as G3-standards. SF concentrations of G1eG3 (a), GRGT-G3 (b), GLGS-G3 (c), AGEG-G3 (d) are shown. The proportion of G3 fragments was calculated (from mol concentrations) as the ratio of a G3 fragment over the sum of GRGT-G3 (band-a), GLGS-G3 (band-b) and AGEG-G3 (band-c) fragments (e). The boxes define the twenty-fifth and seventy-fifth percentile with a line at the median, error bars define the tenth and ninetieth percentile and circles represent individual outliers. *Indicates significance (P < 0.05) between injury and reference groups. Actual P-values for (a) e (d) are shown in Table IV . Diagnostic groups are as in Table I. AGEG-G3 fragments were increased following injury [ Fig. 5(a) ]. A 124 kDa CS1-KEEE fragment (band-b) with an estimated MMP generated N-terminal of ISGL, and a 50 kDa aggrecanase generated GRGT-KEEE fragment (band-c) were also significantly increased during injury [ Fig. 5(a) , Supplementary data Fig. S4(a) ]. G1 fragments in region-A (Mw > 250 kDa; G1eG3 monomers and G1-CS2 with aggrecanase generated KEEE/SELE) and region-B (Mw ¼ 150e250 kDa; G1-CS1 with an estimated MMP generated C-terminal of GVED) were the dominant G1-fragments in the reference group (data not shown). The concentrations of G1 region-B fragments were significantly reduced in the injury groups, while G1 region-C fragments (Mw ¼ 100e150 kDa; G1-keratan sulfate (KS) with unknown C-terminal) were significantly increased during AI, all compared to the reference group [ Fig. 5(a) , Supplementary data Fig. S4(b) ].
These results suggest that there is a high Mw (>100 kDa) aggrecanase generated SF aggrecan injury pattern which is significantly different from the turnover pattern of the REF group [illustrated in Fig. 5(b) ]. This difference in pattern is due to elevated aggrecanase proteolysis against both the IGD and CS2 sites of aggrecan in injured joints.
Discussion
We have previously presented a quantitative Western blot method for aggrecan fragments where we analyzed a few SF-D1 samples from five diagnostic groups 18 . In the present paper we have considerably extended the patient numbers, focusing on AIs and CIs in comparison with knee healthy subjects, and in a detailed analysis provide quantitative and qualitative information on additional aggrecan fragments.
CsCl purification of SF aggrecan together with Western blot analysis allowed quantitative detection of high Mw (>100 kDa) aggrecanase generated fragments from seventy knee injured and ten knee healthy subjects. These measurements showed that directly after injury (within 2 weeks) there was an increased aggrecanase cleavage in the aggrecan IGD, generating ARGS-SELE and ARGS-CS1 fragments. Similarly increased aggrecanase cuts were seen against the aggrecan CS2 sites generating GRGT-G3, GLGS-G3 and AGEG-G3 fragments. The levels of the aggrecanase generated G3 fragments were normalized 2 years after injury, although there was still a difference in the ARGS-SELE/ARGS-CS1 ratio between injury and reference. Further, the SF patterns of G1 and KEEE fragments were also markedly changed after injury. Together these data show that there is a change in the aggrecan turnover lasting many years after knee injury.
Several of the aggrecan fragments found in these SF-D1 samples were generated by aggrecanase digestion in combination with cuts by MMPs (e.g., ARGS-GVED, ISGL-KEEE) or calpains (ARGS-EDLS). Also, MMP generated FFGV fragments have been detected in SF-D1 samples 17 , but calpain generated PGVA and GDLS fragments 32 were not found in these SF-D1 samples (data not shown). Even though some of the MMP and calpain cuts of aggrecan might be involved in normal turnover, it is also possible that these enzymes have an active role in the degradation processes following joint injuries. Knee injuries are accompanied by increased SF levels of proinflammatory cytokines 35 , and increased levels of ARGS fragments have been observed in explant studies when stimulating cartilage with cytokines 22,36e38 . Mechanically injured bovine cartilage discs have an increased mRNA expression of cartilage matrix degrading enzymes 39 which result in proteoglycan and collagen degradation in these tissues 40, 41 . Increased SF levels of proteoglycans and/or aggrecan 2,3 and the aggrecan neoepitope ARGS 15,18 directly after knee injury (i.e., acute phase 0e12 weeks) are well established. Our results (Figs. 2 and 3 , Table II ) support these findings, which are now extended by our Western blot data showing that concentrations of both ARGS-SELE and ARGS-CS1 fragments are increased, and that the ratio of these fragments is constantly higher in the injury group compared to reference for many years after injury. SF-ARGS ELISA measurements can distinguish diseased joints (i.e., arthritis and joint injury) from reference joints with high sensitivity and specificity 15 , and a similar differentiation in Table V Sensitivity and specificity of aggrecanase generated SF ARGS and G3 fragments in distinguishing between injured and healthy knee cartilage. Concentrations (in pmol/ ml SF) of ARGS region-A, ARGS region-B, total ARGS, GRGT-G3, GLGS-G3 and AGEG-G3 fragments were measured in SF-D1 samples using Western blot and human ARGS or bovine G3 standards. The data (in %): comparison between AI (0e12 weeks) and reference (healthy), and between AI (0e12 weeks) plus CI (>52 weeks) and reference. Diagnostic groups were according to Table I Biomarkers AI AIs and CIs AUC Sensitivity Specificity AUC Sensitivity Specificity A 98  97  90  86  74  90  ARGS region B 94  94  90  74  64  90  ARGS total  96  94  90  80  69  90  GRGT-G3  72  71  78  63  60  78  GLGS-G3  75  83  67  63  69  67  AGEG-G3  83  69  89  68  72  67 Sensitivity ¼ the proportion of positives (diseased) correctly identified by the test. Specificity ¼ the proportion of negatives (healthy) correctly identified by the test.
ARGS region
total SF-ARGS was obtained by Western blot measurements when we compared injury group with a reference group (Table V) . SF concentrations of the ARGS-SELE fragment showed the greatest difference between injured and control subjects, although this fragment was not a better biomarker than total ARGS in distinguishing injured from healthy subjects. This suggests that ARGS-ELISA 26 and electrochemiluminescence methods 27 measuring total ARGS are still the best methods for screening large numbers of samples. The aggrecanase generated aggrecan fragment SF-pattern from injured knees (AI þ CI) observed here resembles qualitatively the pattern observed in OA and acute arthritis (Supplementary data Figs. S2 and S3; 16, 17, 33, 34 ). Although the difference in aggrecanase generated fragment pattern between injury and REF was marked, no clear difference was seen between patterns observed early after injury compared to those later after injury.
The aggrecan fragments appearing in SF are proteolytic products of larger G1 fragments (e.g., G1eCS1, G1-SELE/KEEE and G1eG3) present in the cartilage extracellular matrix 16, 17, 33, 42 . Many knee injuries are isolated meniscus tears or combinations of meniscus and anterior/posterior crucial ligament injures 43, 44 , and since the meniscus and the ligaments contain aggrecan 21, 45 it is plausible that theses tissues may contribute to the overall high aggrecan fragment concentrations in SF following injury. Proteolytic cleavage in the IGD of cartilage aggrecan releases the sGAG-containing C-terminal part of the molecule which mainly diffuses out into SF 15, 17, 42 or into media in explant systems 46, 47 . On the other hand, the N-terminal G1 fragments remain in the tissue or are internalized by chondrocytes 46, 48, 49 . The injurious joint insult induces an increase in pro-inflammatory cytokine levels in the damaged joint tissues, which in turn up-regulates aggrecanolytic enzymes, resulting in increased aggrecan degradation. Although aggrecanase activity within the CS2 region has been proposed to be a result of aggrecan maturation 16, 17, 32 , it is interesting to note that these cuts in CS2 were also increased as a result of injury. An explanation for why there is an increased cut in the CS2 region after injury could be that aggrecanase digestion in CS2 is more preferred than cuts in the IGD as shown for bovine 10 and human aggrecan (our data e not shown), and/or that cuts in CS2 facilitate the removal of high Mw aggrecan fragments from injured tissues. This study has some general limitations: (1) There is a big difference in sGAG yield in these preparations which could be explained by heterogeneous SF samples with differences in protein and sGAG concentrations and in viscosities. (2) Enrichment of aggrecan fragments is necessary before analysis by SDS-PAGE and Western blot. Here we used dissociative CsCl centrifugation assuming that the proportion of high Mw (>100 kDa) aggrecan fragments present in the D1 fraction reflects the high Mw in vivo content of SF. (3) There might be differences in the efficiency of electro-transfer of aggrecan fragments with different size and charge, and any differences in the affinity of the antibodies for fragments of different size carrying the same epitope would affect the detected ratio of the signals. (4) The Western blot quantification method has a higher CV compared to methods such as ELISA. Therefore the comparisons between groups were done using subject median values instead of means. (5) We have used human ARGS-and bovine G3-standards (purified from cartilage) in the quantification studies, which make a comparison between ARGS and G3 fragment concentrations difficult. This could be overcome if instead using human recombinant aggrecan fragments as standards.
Our study also has some strengths. The advantage of the Western blot quantification method over more regular methods such as ELISA is that it discriminates between different proteolytic fragments carrying the same epitopes, and therefore allows a more detailed quantitative analysis of the products of aggrecan proteolysis.
We have shown that in patients suffering from acute knee joint injuries, the SF concentrations of several different aggrecanase generated fragments are markedly increased. Both aggrecanase cuts in the IGD and cuts in the aggrecanase CS2 sites are increased. This change in fragment patterns is present several years after the injury. The continued change in aggrecan turnover pattern may contribute to the frequent development of OA following joint injuries 43 .
